Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Nutrients ; 16(8)2024 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-38674927

RESUMO

The excessive activation of glutamate in the brain is a factor in the development of vascular dementia. γ-Oryzanol is a natural compound that has been shown to enhance brain function, but more research is needed to determine its potential as a treatment for vascular dementia. This study investigated if γ-oryzanol can delay or improve glutamate neurotoxicity in an in vitro model of differentiated HT-22 cells and explored its neuroprotective mechanisms. The differentiated HT-22 cells were treated with 0.1 mmol/L glutamate for 24 h then given γ-oryzanol at appropriate concentrations or memantine (10 µmol/L) for another 24 h. Glutamate produced reactive oxygen species and depleted glutathione in the cells, which reduced their viability. Mitochondrial dysfunction was also observed, including the inhibition of mitochondrial respiratory chain complex I activity, the collapse of mitochondrial transmembrane potential, and the reduction of intracellular ATP levels in the HT-22 cells. Calcium influx triggered by glutamate subsequently activated type II calcium/calmodulin-dependent protein kinase (CaMKII) in the HT-22 cells. The activation of CaMKII-ASK1-JNK MAP kinase cascade, decreased Bcl-2/Bax ratio, and increased Apaf-1-dependent caspase-9 activation were also observed due to glutamate induction, which were associated with increased DNA fragmentation. These events were attenuated when the cells were treated with γ-oryzanol (0.4 mmol/L) or the N-methyl-D-aspartate receptor antagonist memantine. The results suggest that γ-oryzanol has potent neuroprotective properties against glutamate excitotoxicity in differentiated HT-22 cells. Therefore, γ-oryzanol could be a promising candidate for the development of therapies for glutamate excitotoxicity-associated neurodegenerative diseases, including vascular dementia.


Assuntos
Ácido Glutâmico , Mitocôndrias , Fármacos Neuroprotetores , Fenilpropionatos , Espécies Reativas de Oxigênio , Ácido Glutâmico/toxicidade , Fenilpropionatos/farmacologia , Animais , Fármacos Neuroprotetores/farmacologia , Camundongos , Linhagem Celular , Espécies Reativas de Oxigênio/metabolismo , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Oryza/química , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Memantina/farmacologia , Apoptose/efeitos dos fármacos , Proteína Quinase Tipo 2 Dependente de Cálcio-Calmodulina/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo
2.
Environ Toxicol ; 2024 Mar 18.
Artigo em Inglês | MEDLINE | ID: mdl-38497692

RESUMO

Chondrosarcoma is a malignant bone tumor that arises from abnormalities in cartilaginous tissue and is associated with lung metastases. Extracellular vesicles called exosomes are primarily used as mediators of intercellular signal transmission to control tumor metastasis. Visfatin is an adipokine reported to enhance tumor metastasis, but its relationship with exosome generation in chondrosarcoma motility remains undetermined. Our results found that overexpressing visfatin augments the production of exosomes from chondrosarcoma cells. Visfatin-treated chondrosarcoma exosomes educate macrophage polarization towards the M2 but not M1 phenotype. Interestingly, M2 macrophages polarized by exosomes return to chondrosarcoma cells to facilitate cell motility. According to these findings, chondrosarcoma cells emit more exosomes when treated with visfatin. The stimulation of exosome generation by visfatin polarizes M2 macrophages and enhances the motility of chondrosarcoma.

3.
Chin J Physiol ; 65(3): 151-157, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35775534

RESUMO

Gomisin A is a dietary lignan compound isolated from the fruit of Schisandra chinensis and has many pharmacological properties, including hepato-protective, anti-diabetic, and anti-oxidative activities. However, the benefit of gomisin A is still not well understood. The action of gomisin A is diverse. However, the effect of gomisin A on Ca2+ signaling in prostate cancer cells is unknown. Ca2+ is a pivotal second envoy that triggers and regulates cellular processes such as apoptosis, fertilization, energy transduction, secretion, and protein activation. The goal of this study was to explore the action of gomisin A on [Ca2+]i and cytotoxicity in PC3 prostate cancer cells. Gomisin A at 100-200 µM provoked [Ca2+]i raises. 20% of the response was reduced by removing external Ca2+. The Ca2+ influx provoked by gomisin A was suppressed by 20% by store-caused Ca2+ entry suppressors: econazole, SKF96365, nifedipine; also by phorbol 12-myristate 13 acetate and GF109203X. Without external Ca2+, gomisin A-caused [Ca2+]i raises were abolished by thapsigargin. In contrast, gomisin A suppressed the [Ca2+]i raises caused by thapsigargin. U73122 fell short to change gomisin A-caused [Ca2+]i responses. Gomisin A (20-100 µM) elicited cytotoxicity in a dose-associated fashion. Blockade of [Ca2+] elevations with 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid/acetoxy methyl failed to inhibit cytotoxicity of gomisin A. Collectively, gomisin A evoked [Ca2+]i raises and provoked cytotoxicity in a Ca2+-dissociated fashion in prostate cancer cells.


Assuntos
Lignanas , Neoplasias da Próstata , Cálcio/metabolismo , Linhagem Celular Tumoral , Sobrevivência Celular , Ciclo-Octanos , Dioxóis , Humanos , Lignanas/farmacologia , Masculino , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/metabolismo , Tapsigargina/farmacologia , Fosfolipases Tipo C/metabolismo
4.
Pharmaceuticals (Basel) ; 13(11)2020 Oct 23.
Artigo em Inglês | MEDLINE | ID: mdl-33114121

RESUMO

PURPOSE: To evaluate the pharmacological effects of propranolol treatment of patients with central serous chorioretinopathy (CSCR) over 4 months. RESULTS: Among the 89 male and 31 female patients, the mean BCVA decreased to 0.42 ± 0.08 logMAR during CSCR attacks. Oral propranolol showed good effectiveness in reducing CSCR signs after at least 4 months of treatment. The final BCVA of the patients in groups 1 and 2 was 0.09 ± 0.01 and 0.19 ± 0.03 logMAR, respectively (p < 0.05). Moreover, the mean complete remission time in groups 1 and 2 was 1.9 and 3.5 months, respectively (p < 0.05), while the "success" rate in groups 1 and 2 was 95.0% (57/60) and 78.3% (47/60), respectively (p < 0.05). The recurrence rate in groups 1 and 2 was 5.3% (3/57) and 25.5% (12/47) after a further 5 months of follow-up, respectively (p < 0.05). MATERIALS AND METHODS: One hundred and twenty patients were enrolled and randomly divided into two groups that both underwent a visual acuity test and optical coherence tomography (OCT) scanning, between April and December 2017. The 60 patients in group 1 were requested to take propranolol for 4 months, while the other 60 subjects (group 2) received placebo therapy during the same period. The best-corrected visual acuity (BCVA) of every volunteer and an OCT image of each patient were checked and recorded at the beginning of the study and each week thereafter. If the signs of CSCR disappeared completely from the OCT scans, the case was considered a "success" and treatment stopped at once. However, the "success" subjects were further evaluated in follow-ups throughout the next 5 months to determine the rate of recurrence in groups 1 and 2. The time of total complete remission of CSCR from the OCT scans was also measured in groups 1 and 2. CONCLUSION: CSCR patients revealed an excellent prognosis and success rate of 95.0% after taking propranolol. The treatment was able to enhance subretinal fluid (SRF) absorption, shorten the time to total complete remission, and significantly decrease CSCR recurrence. As such, we suggest that taking propranolol may be an alternative and viable choice for CSCR patients, given that the new method was shown to be safe, cheap, effective, well tolerated and convenient.

5.
Phytochemistry ; 143: 186-193, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28825980

RESUMO

The fruits of Psoralea corylifolia, known as Psoraleae Fructus (Buguzhi in Chinese), are traditionally used for the treatment of spermatorrhea, nephritis, asthma, pollakiuria, and various inflammatory diseases. Three previously undescribed isoflavone derivatives, 7-O-methylcorylifol A, 7-O-isoprenylcorylifol A, and 7-O-isoprenylneobavaisoflavone, have been isolated from the fruits of P. corylifolia, together with 9 known compounds. The structures of these compounds were determined through spectroscopic and MS analyses. Among the isolated compounds, 7-O-methylcorylifol A and psoralen exhibited potent inhibition (IC50 values ≤ 10.89 µM) of superoxide anion generation by human neutrophils in response to N-formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B (fMLP/CB). 7-O-Isoprenylcorylifol A, 7-O-isoprenylneobavaisoflavone, and 12,13-dihydro-12,13-epoxybakuchiol inhibited fMLP/CB-induced elastase release with IC50 values ≤ 14.30 µM. In addition, 7-O-isoprenylcorylifol A, bakuchiol, 12,13-dihydro-12,13-epoxybakuchiol, and psoralidin showed potent inhibition with IC50 values ≤ 36.65 µM, against lipopolysaccharide (LPS)-induced nitric oxide (NO) generation.


Assuntos
Anti-Inflamatórios não Esteroides/isolamento & purificação , Anti-Inflamatórios não Esteroides/farmacologia , Isoflavonas/isolamento & purificação , Isoflavonas/farmacologia , Psoralea/química , Animais , Anti-Inflamatórios não Esteroides/química , Benzofuranos , Cumarínicos , Frutas , Humanos , Isoflavonas/química , Lipopolissacarídeos/farmacologia , Camundongos , N-Formilmetionina Leucil-Fenilalanina , Neutrófilos/efeitos dos fármacos , Óxido Nítrico/biossíntese , Ressonância Magnética Nuclear Biomolecular , Elastase Pancreática/antagonistas & inibidores , Fenóis , Fenilalanina , Superóxidos
6.
J Recept Signal Transduct Res ; 37(2): 189-199, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27401208

RESUMO

PURPOSE: The transforming growth factor-beta (TGF-ß) pathway is an important in the initiation and progression of cancer. Due to a strong association between an elevated colorectal cancer risk and increase fecal excretion of cholest-4-en-3-one, we aim to determine the effects of cholest-4-en-3-one on TGF-ß signaling in the mink lung epithelial cells (Mv1Lu) and colorectal cancer cells (HT29) in vitro. METHODS: The inhibitory effects of cholest-4-en-3-one on TGF-ß-induced Smad signaling, cell growth inhibition, and the subcellular localization of TGF-ß receptors were investigated in epithelial cells using a Western blot analysis, luciferase reporter assays, DNA synthesis assay, confocal microscopy, and subcellular fractionation. RESULTS: Cholest-4-en-3-one attenuated TGF-ß signaling in Mv1Lu cells and HT29 cells, as judged by a TGF-ß-specific reporter gene assay of plasminogen activator inhibitor-1 (PAI-1), Smad2/3 phosphorylation and nuclear translocation. We also discovered that cholest-4-en-3-one suppresses TGF-ß responsiveness by increasing lipid raft and/or caveolae accumulation of TGF-ß receptors and facilitating rapid degradation of TGF-ß and thus suppressing TGF-ß-induced signaling. CONCLUSIONS: Our results suggest that cholest-4-en-3-one inhibits TGF-ß signaling may be due, in part to the translocation of TGF-ß receptor from non-lipid raft to lipid raft microdomain in plasma membranes. Our findings also implicate that cholest-4-en-3-one may be further explored for its potential role in colorectal cancer correlate to TGF-ß deficiency.


Assuntos
Neoplasias Colorretais/genética , Inibidor 1 de Ativador de Plasminogênio/genética , Proteínas Serina-Treonina Quinases/genética , Receptores de Fatores de Crescimento Transformadores beta/genética , Fator de Crescimento Transformador beta1/genética , Animais , Colestenonas/administração & dosagem , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/patologia , Células Epiteliais/patologia , Células HT29 , Humanos , Pulmão/patologia , Microdomínios da Membrana/efeitos dos fármacos , Microdomínios da Membrana/genética , Microdomínios da Membrana/metabolismo , Vison/genética , Fosforilação , Inibidor 1 de Ativador de Plasminogênio/biossíntese , Proteínas Serina-Treonina Quinases/biossíntese , Proteólise/efeitos dos fármacos , Receptor do Fator de Crescimento Transformador beta Tipo I , Receptores de Fatores de Crescimento Transformadores beta/biossíntese , Transdução de Sinais/efeitos dos fármacos , Fator de Crescimento Transformador beta1/biossíntese
7.
Fitoterapia ; 117: 16-21, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28012920

RESUMO

Two new naphthofuranone derivatives, 11-hydroxy-2-O-methylhibiscolactone A (1) and O-methylhibiscone D (2), have been isolated from the stems of Pachira aquatica, together with 18 known compounds (3-20). The structures of two new compounds were determined through spectroscopic and MS analyses. Among the isolated compounds, 11-hydroxy-2-O-methylhibiscolactone A (1), isohemigossylic acid lactone-7-methyl ether (4), gmelofuran (6), and 5-hydroxyauranetin (8) exhibited inhibition (IC50≤28.84µM) of superoxide anion generation by human neutrophils in response to N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP).


Assuntos
Anti-Inflamatórios/química , Bombacaceae/química , Furanos/química , Neutrófilos/efeitos dos fármacos , Superóxidos/metabolismo , Adulto , Anti-Inflamatórios/isolamento & purificação , Células Cultivadas , Furanos/isolamento & purificação , Humanos , Estrutura Molecular , N-Formilmetionina Leucil-Fenilalanina , Neutrófilos/metabolismo , Extratos Vegetais/química , Caules de Planta/química , Adulto Jovem
8.
Molecules ; 21(10)2016 Oct 17.
Artigo em Inglês | MEDLINE | ID: mdl-27763530

RESUMO

Two new sesquiterpenoids-13-hydroxycurzerenone (1) and 1-oxocurzerenone (2)-have been isolated from the rhizomes of Curcuma zedoaria, together with 13 known compounds (3-15). The structures of two new compounds were determined through spectroscopic and MS analyses. Among the isolated compounds, 13-hydroxycurzerenone (1), 1-oxocurzerenone (2), curzerenone (3), germacrone (4), curcolone (5), procurcumenol (6), ermanin (7), curcumin (8), and a mixture of stigmast-4-en-3,6-dione (12) and stigmasta-4,22-dien-3,6-dione (13) exhibited inhibition (with inhibition % in the range of 21.28%-67.58%) against collagen-induced platelet aggregation at 100 µM. Compounds 1, 5, 7, 8, and the mixture of 12 and 13 inhibited arachidonic acid (AA)-induced platelet aggregation at 100 µM with inhibition % in the range of 23.44%-95.36%.


Assuntos
Curcuma/química , Agregação Plaquetária/efeitos dos fármacos , Rizoma/química , Sesquiterpenos/farmacologia , Ácido Araquidônico/efeitos adversos , Estrutura Molecular , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Sesquiterpenos/química
9.
Molecules ; 20(10): 18551-64, 2015 Oct 12.
Artigo em Inglês | MEDLINE | ID: mdl-26473818

RESUMO

A new limonoid, swietemacrophin (1), was isolated from the seeds of Swietenia macrophylla, together with five known compounds 2-6. The structure of 1 was determined through extensive 1D/2D-NMR and mass-spectrometric analyses. Swietemacrophin (1), humilinolide F (2), 3,6-O,O-diacetylswietenolide (3), 3-O-tigloylswietenolide (4), and swietemahonin E (5) exhibited inhibition (IC50 values≤45.44 µM) of superoxide anion generation by human neutrophils in response to formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP). Compounds 1, 4, 5, and swietenine (6) showed potent inhibition with IC50 values≤36.32 µM, against lipopolysaccharide (LPS)-induced nitric oxide (NO) generation.


Assuntos
Anti-Inflamatórios/isolamento & purificação , Limoninas/isolamento & purificação , Meliaceae/química , Sementes/química , Triterpenos/isolamento & purificação , Anti-Inflamatórios/química , Anti-Inflamatórios/farmacologia , Humanos , Concentração Inibidora 50 , Limoninas/química , Limoninas/farmacologia , Lipopolissacarídeos/antagonistas & inibidores , Lipopolissacarídeos/farmacologia , N-Formilmetionina Leucil-Fenilalanina/análogos & derivados , N-Formilmetionina Leucil-Fenilalanina/antagonistas & inibidores , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Neutrófilos/citologia , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Óxido Nítrico/antagonistas & inibidores , Óxido Nítrico/biossíntese , Extratos Vegetais/química , Cultura Primária de Células , Relação Estrutura-Atividade , Superóxidos/antagonistas & inibidores , Triterpenos/química , Triterpenos/farmacologia
10.
Int J Mol Sci ; 16(9): 21950-8, 2015 Sep 11.
Artigo em Inglês | MEDLINE | ID: mdl-26378524

RESUMO

Two new 24-homoscalarane sesterterpenoids, felixins F (1) and G (2), were isolated from the sponge Ircinia felix. The structures of new homoscalaranes 1 and 2 were elucidated by extensive spectroscopic methods, particularly with one-dimensional (1D) and two-dimensional (2D) NMR, and, by comparison, the spectral data with those of known analogues. The cytotoxicity of 1 and 2 against the proliferation of a limited panel of tumor cell lines was evaluated and 1 was found to show cytotoxicity toward the leukemia K562, MOLT-4, and SUP-T1 cells (IC50 ≤ 5.0 µM).


Assuntos
Poríferos/química , Sesterterpenos/química , Sesterterpenos/toxicidade , Animais , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Humanos , Estrutura Molecular
11.
Chem Biodivers ; 11(9): 1374-80, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25238078

RESUMO

Two new thymol (=5-methyl-2-(1-methylethyl)phenol) derivatives, 8,10-didehydro-9-(3-methylbutanoyl)thymol 3-O-tiglate (1) and 9-O-angeloyl-8-methoxythymol 3-O-isobutyrate (2), were isolated from the root of Eupatorium cannabinum ssp. asiaticum, together with six known compounds, 3-8. The structures of 1 and 2 were determined through extensive 1D/2D-NMR and MS analyses. Among the isolates, 9-acetoxy-8,10-epoxythymol 3-O-tiglate (3) was the most cytotoxic, with IC50 values of 0.02±0.01, 1.02±0.07, and 1.36±0.12 µg/ml, respectively, against DLD-1, CCRF-CEM, and HL-60 cell lines. In addition, 10-acetoxy-9-O-angeloyl-8-hydroxythymol (4) and eupatobenzofuran (6) exhibited cytotoxicities, with IC50 values of 1.14±0.16 and 2.63±0.22, and 7.63±0.94 and 2.31±0.14 µg/ml, respectively, against DLD-1 and CCRF-CEM cell lines.


Assuntos
Eupatorium/química , Raízes de Plantas/química , Timol/isolamento & purificação , Linhagem Celular , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Concentração Inibidora 50 , Espectroscopia de Ressonância Magnética , Timol/química , Timol/farmacologia
12.
Molecules ; 19(9): 14667-86, 2014 Sep 16.
Artigo em Inglês | MEDLINE | ID: mdl-25230122

RESUMO

To date, no study has been conducted to explore the bioactivity of the crinoid Comanthus bennetti. Here we report the anti-inflammatory properties of comaparvin (5,8-dihydroxy-10-methoxy-2-propylbenzo[h]chromen-4-one) based on in vivo experiments. Our preliminary screening for anti-inflammatory activity revealed that the crude extract of Comanthus bennetti significantly inhibited the expression of pro-inflammatory proteins in lipopolysaccharide (LPS)-stimulated murine RAW 264.7 macrophage cells. Comaparvin isolated from crinoids significantly decreased the expression of inducible nitric oxide synthase (iNOS) protein and mRNA in LPS-stimulated macrophage cells. Moreover, our results showed that post-treatment with comaparvin significantly inhibited mechanical allodynia, thermal hyperalgesia and weight-bearing deficits in rats with carrageenan-induced inflammation. Comaparvin also attenuated leukocyte infiltration and iNOS protein expression in carrageenan-induced inflamed paws. These results suggest that comaparvin is a potential anti-inflammatory therapeutic agent against inflammatory pain.


Assuntos
Anti-Inflamatórios/administração & dosagem , Cromonas/administração & dosagem , Cromonas/química , Equinodermos/química , Inflamação/tratamento farmacológico , Óxido Nítrico Sintase Tipo II/biossíntese , Animais , Anti-Inflamatórios/química , Carragenina/toxicidade , Regulação da Expressão Gênica/efeitos dos fármacos , Inflamação/induzido quimicamente , Inflamação/genética , Leucócitos/efeitos dos fármacos , Leucócitos/patologia , Lipopolissacarídeos/toxicidade , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Camundongos , Óxido Nítrico/metabolismo , Ratos
13.
Chem Pharm Bull (Tokyo) ; 62(1): 106-11, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24390500

RESUMO

Certain amide-containing anthraquinone, xanthone, and carbazole derivatives have been synthesized and evaluated in vitro for their antiproliferative activities against a panel of human cancer cell lines including nasopharyngeal carcinoma (NPC-TW01), lung carcinoma (NCI-H661), and leukemia (Jurkat). Among them, 2-(9,10-dioxo-9,10-dihydroanthracen-2-yloxy)-N-(naphthalen-2-yl)acetamide (13) was the most active against NPC-TW01 with an IC50 value of 2.62 µM while its xanthone and dibenzofuran counterparts, 14 and 15, were inactive with an IC50 value of 16.10 and 11.09 µM, respectively. Studies on NPC-TW01 cell cycle distribution revealed that compound 13 inhibited proliferation of NPC-TW01 by the alteration of cell division and the accumulation of cells in G0/G1 phase.


Assuntos
Amidas/química , Antraquinonas/química , Carbazóis/química , Proliferação de Células/efeitos dos fármacos , Xantonas/química , Linhagem Celular Tumoral , Fase G1/efeitos dos fármacos , Humanos , Fase de Repouso do Ciclo Celular/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA